Jyong Biotech (MENS) vs Spruce Biosciences (SPRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Spruce Biosciences (SPRB) has outperformed Jyong Biotech (MENS) over the past year, losing 63.8% versus a loss of 95.3%. Jyong Biotech is the larger company by market cap ($110.2 million vs $109.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MENS | SPRB |
|---|---|---|
| Share price | $1.45 | $38.00 |
| Market cap | $110.24M | $109.21M |
| 1-day change | -17.14% | -6.15% |
| YTD return | -63.29% | -56.38% |
| 1-year return | -95.28% | -63.81% |
| 5-year return | — | -99.75% |
| Forward P/E | — | 11.79 |
| EPS (TTM) | $-0.06 | $-33.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-4.67M | $-38.97M |
| 52-week high | $38.88 | $111.00 |
| 52-week low | $1.43 | $38.00 |
| Distance from 52-week high | -96.27% | -65.77% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +288.00% |
| Average volume | 44.23K | 89.33K |
| Shares outstanding | 74.23M | 2.87M |
| Employees | 27 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SPRB has outperformed MENS by 31.5 percentage points over the past year.
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Spruce Biosciences
SPRB stock →Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
MENS vs SPRB FAQ
Which is bigger, Jyong Biotech or Spruce Biosciences?
Jyong Biotech (MENS) is larger, with a market capitalization of $110.24M compared with $109.21M for Spruce Biosciences (SPRB).
Which stock has performed better over the past year, MENS or SPRB?
SPRB returned -63.81% over the past 12 months, compared with -95.28% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Jyong Biotech and Spruce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.